Optimizing thiopurine therapy in inflammatory bowel disease. - Wikidata - wikimedia - TriplyDB

Optimizing thiopurine therapy in inflammatory bowel disease.

Optimizing thiopurine therapy in inflammatory bowel disease.

http://www.wikidata.org/entity/Q37800458

about

Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study Review article: remission rates achievable by current therapies for inflammatory bowel disease.First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?Translational research and efficacy of biologics in Crohn's disease: a cautionary tale.What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?The role of thiopurine metabolite monitoring in inflammatory bowel disease.Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.Optimizing pharmacologic management of inflammatory bowel disease.Biomarkers in Search of Precision Medicine in IBD.Pharmacogenetics of inflammatory bowel disease.Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis.

P2860

Q35862806-D4BD185E-9DAE-4210-942B-87BC4FC584C0 Q37842605-D9067725-47A3-4FF0-85B7-40323C66832C Q38086355-274DA816-717D-48A2-BD99-D8758132A9D1 Q38177338-C76B334A-5BB0-44EA-A17B-720528802A2C Q38191583-FD4EAF6E-939E-4FE1-A160-E508C903640A Q38200692-AB7DCDF1-C118-4443-9504-440A7D0DA6D6 Q38323592-50852D9A-5292-4714-9935-902E36EB203F Q38687407-B7DB3FB7-325F-4E8D-8173-C2F09211F8A5 Q38964878-F4372516-137D-4BDD-AF08-129650091FFF Q41673937-938B6BC8-71A4-458A-9274-B505B4DCA56D Q50495588-33A47A43-7741-4DF0-BCAC-CD000C1CF3C4 Q54242863-D64A113E-34C5-4579-A28A-802E35838F40

P2860

Optimizing thiopurine therapy in inflammatory bowel disease.

http://www.wikidata.org/entity/Q37800458

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Optimizing thiopurine therapy in inflammatory bowel disease.

@en

Optimizing thiopurine therapy in inflammatory bowel disease.

@nl

type

label

Optimizing thiopurine therapy in inflammatory bowel disease.

@en

Optimizing thiopurine therapy in inflammatory bowel disease.

@nl

prefLabel

Optimizing thiopurine therapy in inflammatory bowel disease.

@en

Optimizing thiopurine therapy in inflammatory bowel disease.

@nl

P1433

Q37800458-962E7063-44B3-4628-9C39-4BA9D1A4B04C

P1476

Q37800458-EF7F645A-239C-4393-973E-BA7D13BD8002

P2093

Q37800458-AD3AA7C0-4BB9-4E87-8623-60F0DD14661D

Q37800458-E06D8F01-F84E-45C6-8736-F5236F9337DD

P2860

Q37800458-0394228F-1420-4F3E-AF8E-318E89602AB7

Q37800458-04C60792-DB29-4176-8B46-B76900D2E198

Q37800458-05A797F8-244D-4C40-A343-4DC7AE178719

Q37800458-062F2C9F-90C7-4184-9B3C-BED76B102080

Q37800458-157AC463-B2E4-4C34-9807-52396C1EA906

Q37800458-173B348D-E812-48C8-9C9A-5DDC082D878E

Q37800458-1981A80D-EF07-43A5-AEEC-FDD800888FBF

Q37800458-1BD8E90D-CEBB-43C7-A3FA-C3D3F0542855

Q37800458-1F6D64C7-AD31-4758-850E-7FB84E307491

Q37800458-21949389-0F33-46B5-A1A8-E3C7A40BB62A

P304

Q37800458-921B039C-14F5-430D-BAA1-A1A2C8D7CD3F

P31

Q37800458-E133DB81-3562-4163-AC3D-733C575F6EC7

P356

Q37800458-18A797D2-6AA0-4F95-A156-EAF6448196CE

P433

Q37800458-0F1E9E77-24DE-45BB-9A64-3E982B77EB0C

P478

Q37800458-C1D53786-C952-48D0-B1BD-CD13F23E17CD

P50

Q37800458-2F66930B-916E-420E-A3CE-A5A7D5C15F07

P577

Q37800458-FFD5FEF6-5767-46E7-9759-D90C1429FA85

P5875

Q37800458-D0DC7DA9-00BE-49BD-948F-2C86E4AE3B64

P698

Q37800458-E1377872-C3FA-4A1F-B6F6-D5989C7144E3

P921

Q37800458-57AAF2C6-6C7E-47F3-AA79-75CF5E5B597A

Q37800458-DA3DCF1B-AC22-4C9B-B4F2-F54778EA59F4

P356

P1433

Inflammatory Bowel Diseases

P1476

Optimizing thiopurine therapy in inflammatory bowel disease.

@en

P2093

Jean-Baptiste Chevaux

http://www.w3.org/2001/XMLSchema#string

Miles P Sparrow

http://www.w3.org/2001/XMLSchema#string

P2860

Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression.

Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.

6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.

Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine

Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.

P304

1428-1435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.21494

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Laurent Peyrin-Biroulet

P577

2010-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47431005

http://www.w3.org/2001/XMLSchema#string

P698

20949566

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases